

ARTEMIS GLOBAL LIFE SCIENCES LIMITED

(Formerly - PTL PROJECTS LIMITED)

Regd Off. : 414/1, 4th Floor, DDA Commercial Complex, District Centre, Janakpuri, New Delhi -110058

CIN : U85191DL2011PLC216530

CIN- L85191DL2011PLC216530

04th February, 2019

The Secretary National Stock Exchange of India Ltd Exchange Plaza, Bandra-Kurla Complex, Bandra (E), Mumbai – 400051 Trading Symbol: AGLSL	The Secretary BSE Ltd PhirozeJeejeebhoy Towers, Dalal Street, Mumbai – 400001 Scrip Code:540616
---	--

Sub: Outcome of the Board Meeting held on 04th February, 2019

Dear Sir/ Madam,

In terms of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, we wish to inform you that Board of Directors of the Company in their meeting held on 04.02.2019 have inter alia, considered and approved the un-audited financial results (standalone & consolidated) for the quarter ended 31st December, 2018 as recommended by Audit Committee.


Pursuant to Regulation 33 of SEBI (Listing Obligations Disclosure Requirements) Regulations, 2015, a copy of duly signed un-audited financial results (standalone & consolidated), along with the Limited Review report by statutory auditor of the Company thereon is enclosed.

The Board Meeting commenced at 01:45 p.m. and concluded at 02:25 p.m.

Please take the above information on your records.

Thanking you
Yours Faithfully

For Artemis Global Life Sciences Limited


Anuj Sood
Company Secretary (A35276)
D-6/10, 3rd Floor, Rana Pratap Bagh
New Delhi-110007

Corporate off : SF-202, Peach Tree, C-Block, Sushant Lok-1, Gurgaon - 122002

Website : www.aglsl.in • E-mail: investor@aglsl.in • Tel. 0124 - 4262305/07 • Fax 0124 - 4262306

ANAND DUA & ASSOCIATES

Chartered Accountants

Flat No 11, Pocket-7, Sector-12,
Dwarka, New Delhi-110 078
Email: anand.dua@gmail.com
Ph: 47021279

Review report

To

The Board of Directors

Artemis Global Life Sciences Limited

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results (the Statement') of Artemis Global Life Sciences Limited ('the Company') for the half year ended 31st December 2018, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated 05th July, 2016.
2. The preparation of the statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, "Interim Financial Reporting" ("Ind AS 34") prescribed under Section 133 of the Companies Act, 2013, read with Rule 3 of Companies (Indian Accounting Standards) Rules 2015, as amended, and the Circular is the responsibility of the Company's management and has been approved by the Board of Directors of the company. Our responsibility is to issue a report on the statement based on our review
3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of the Company's personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as mentioned in paragraphs 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with applicable accounting standards ("Ind AS") prescribed under section 133 of the Companies Act, 2013 and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated 05th July, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: New Delhi
Date: 04/02/2019

For Anand Dua & Associates
Chartered Accountants
FRN: 04263N



(Anand Dua)
Partner
M.No. 083503

ARTEMIS GLOBAL LIFE SCIENCES LIMITED

(Formerly - PTL PROJECTS LIMITED)

Regd Office : 414/1, 4th Floor, DDA Commercial Complex, District Centre, Janakpuri, New Delhi - 110058

CIN : U85191DL2011PLC216530

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2018

(Rs. in Lakh)

S No.	Particulars	Quarter ended			Nine Months ended		year ended
		31-Dec-18	30-Sep-18	31-Dec-17	31-Dec-18	31-Dec-17	31-Mar-18
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Revenue from operations*	10.20	10.20	10.20	30.60	30.60	40.80
2	Other income	-	-	-	-	19.23	-
3	Total Income	10.20	10.20	10.20	30.60	49.83	40.80
	Expenses						
	Employee Benefits expenses	6.63	5.74	3.76	18.52	11.24	15.45
	Finance costs	-	-	-	-	-	-
	Depreciation and amortization expense	3.80	3.81	3.85	11.37	11.02	14.74
	Other expenses	10.14	14.75	9.99	33.12	28.92	37.43
4	Total expenses	20.57	24.30	17.60	63.01	51.18	67.62
5	Profit/(Loss) before Tax and exceptional items	(10.37)	(14.10)	(7.40)	(32.41)	(1.35)	(26.82)
6	Exceptional Items	-	-	-	-	11.38	10.99
7	Profit/(Loss) before tax	(10.37)	(14.10)	(7.40)	(32.41)	(12.73)	(37.81)
8	Tax Expense						
	Current Tax	-	-	2.25	-	2.25	2.99
	Deferred tax	(2.06)	(2.06)	(4.14)	(6.19)	(2.61)	(10.92)
	Total tax expense	(2.06)	(2.06)	(1.89)	(6.19)	(0.36)	(7.93)
9	Profit/ (Loss) for the period	(8.31)	(12.04)	(5.51)	(26.22)	(12.37)	(29.88)
10	Other comprehensive income						
I	Items that will not be reclassified to profit or loss						
a	gains / (losses) on defined benefit plans	-	-	-	-	-	-
b	Deferred tax adjustment on revaluation	-	-	-	-	-	-
c	Income tax relating to items that will not be reclassified to profit & loss	-	-	-	-	-	-
II	Net other comprehensive income not to be reclassified to profit or loss in subsequent periods:	-	-	-	-	-	-
	Other comprehensive income for the period, net of income tax	-	-	-	-	-	-
11	Total comprehensive income/(loss) ('OCI')	(8.31)	(12.04)	(5.51)	(26.22)	(12.37)	(29.88)
12	Paid up equity share capital (Face value Rs. 2/- each)	1,323.77	1,323.77	1,323.77	1,323.77	1,323.77	1,323.77
13	Other equity excluding revaluation reserve (as per balance sheet of previous accounting year)	**	**	**	**	**	14,529.92
14	Earning per share (Face value Rs. 2/- each) (refer note 7)						
	Basic (Rs.)	(0.01)	(0.02)	(0.01)	(0.04)	(0.02)	(0.05)
	Diluted (Rs.)	(0.01)	(0.02)	(0.01)	(0.04)	(0.02)	(0.05)

* Medical Equipment Lease rentals received from Artemis Medicare Services Ltd.

** Not required to be shown



OK

ANAND DUA & ASSOCIATES

Chartered Accountants

Flat No 11, Pocket-7, Sector-12,

Dwarka, New Delhi-110 078

Email: anand.dua@gmail.com

Ph: 47021279

Review report

To

The Board of Directors

Artemis Global Life Sciences Limited

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results (the Statement') of Artemis Global Life Sciences Limited ('the Company') and its subsidiaries (the Company and its subsidiaries constitute 'the Group') for the half year ended 31st December 2018, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated 05th July, 2016.
2. The preparation of the statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, "Interim Financial Reporting" ("Ind AS 34") prescribed under Section 133 of the Companies Act, 2013, read with Rule 3 of Companies (Indian Accounting Standards) Rules 2015, as amended, and the Circular is the responsibility of the Company's management and has been approved by the Board of Directors of the company. Our responsibility is to issue a report on the statement based on our review.
3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of the Company's personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. We did not review the interim financial results of the subsidiaries included in the Statement whose interim financial results reflect the Group's share in the profit before tax is Rs 2,592.71 lakhs for the nine months ended 31st December 2018, and the Group's share in the profit after tax of Rs 1517.67 lakhs for the nine months ended 31st December 2018 as considered in the Statement of the Group. These financial results have been reviewed by other auditors whose report has been furnished to us by the Management. Our report on the Statement of the Group, in so far as it related to the amounts and disclosures included in respect of the subsidiaries, is based solely on the reports of the other auditors.
5. Based on our review conducted as mentioned in paragraphs 3 and 4 above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with applicable accounting standards ("Ind AS") prescribed under section 133 of the Companies Act, 2013 and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated 05th July, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: New Delhi

Date: 04/02/2019

For Anand Dua & Associates

Chartered Accountants

FRN: 04263N



(Anand Dua)

Partner

M.No. 083503

Notes

1. The above results for the quarter/ Nine months ended December 31, 2018 were reviewed by the Audit Committee & approved by the Board of Directors at its meeting held on February 4th, 2019. The statutory auditors have expressed unmodified opinion on the aforesaid results.
2. With effect from April 01, 2018, the Company has adopted IND AS-115 ('Revenue from contracts with customers') using the cumulative effect method and accordingly these financial results are prepared in accordance with recognition and measurement principles laid down in IND AS- 115. There were no adjustments required to the retained earnings as at April 01, 2018. Also, the application of IND AS-115 did not have any significant impact on recognition and measurement of revenue and related items in the financial results of the Company.
3. The Company's operation predominantly comprise of only one segment - income from lease of medical equipments to Artemis Medicare Services Ltd. and therefore the figures shown above relate to that segment.
4. The Company and its holding company i.e. Artemis Health Sciences Ltd, its ultimate holding company i.e. Artemis Global Life Sciences Ltd and its fellow subsidiary company i.e. Athena Eduspark Limited have decided to merge and the proposed Composite Scheme of Amalgamation between the aforesaid Companies and their respective shareholders and creditors under section 230 to 232 and other applicable provisions of Companies Act, 2013 have been approved in the meeting of the Board of Directors held on 09th May, 2018. Respective shareholders and Creditors have also approved proposed Composite Scheme of Amalgamation in their meetings held on 27th Jan 2019. Scheme of Amalgamation is subject to clearance by National Company Law Tribunal & other regulatory approvals.
5. The above financial results have been prepared in accordance with the companies (Indian Accounting Standards) Rules, 2015 (Ind AS), as prescribed under section 133 of the Companies Act 2013, and the other recognised accounting practices and policies to the extent applicable.
6. EPS is not annualised for the quarter/ Nine months ended December 31, 2018 & December 31, 2017 and quarter ended September 30, 2018 .
7. Previous period figures have been regrouped / reclassified wherever necessary to correspond with the current period classification / disclosures.



For and on behalf of the Board of Directors of
ARTEMIS GLOBAL LIFE SCIENCES LIMITED

Onkar S. Kanwar

ONKAR S. KANWAR
CHAIRMAN

PLACE: GURUGRAM
DATE: FEBRUARY 4, 2018

ARTEMIS GLOBAL LIFE SCIENCES LIMITED

(Formerly - PTL PROJECTS LIMITED)

Regd Office : 414/1, 4th Floor, DDA Commercial Complex, District Centre, Janakpuri, New Delhi - 110058

CIN : U85191DL2011PLC216530

STATEMENT OF UNAUDITED CONSOLIDATED RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2018.

(Rs. in Lakh)

S No	Particulars	Artemis Global Life Sciences Ltd					
		Quarter ended			Nine Months ended		Year ended
		31-Dec-18 (Unaudited)	30-Sep-18 (Unaudited)	31-Dec-17 (Not Subjected to Limited Review)	31-Dec-18 (Unaudited)	31-Dec-17 (Not Subjected to Limited Review)	31-Mar-18 (Audited)
1	Revenue from operations (Net off Inter company transaction)	13,903.84	14,088.98	12,016.00	40,635.89	36,567.78	50,278.71
2	Other income	62.59	89.48	90.10	268.93	341.93	429.90
3	Total Income	13,966.43	14,178.46	12,106.10	40,904.82	36,909.71	50,708.61
	Expenses						
	Purchases of pharmacy drugs & medical consumables	3,279.35	3,321.06	2,790.96	9,591.70	9,143.32	12,083.89
	Purchases of Stock in Trade	34.71	48.00	35.50	111.33	102.73	137.15
	Changes in inventories of pharmacy drugs, Medical consumables & Stock in Trade	19.08	(80.24)	224.16	(50.50)	(36.43)	(8.31)
	Employee benefit expenses	2,504.94	2,336.67	2,301.40	7,198.09	6,716.82	9,068.24
	Finance Cost (Net off Inter company transaction)	309.58	298.93	214.27	811.46	683.31	942.03
	Depreciation and amortization expense	501.73	495.57	477.24	1,487.55	1,406.42	1,880.56
	Other expenses	6,353.94	6,757.28	5,610.51	19,194.89	17,304.54	23,103.62
4	Total expenses	13,003.33	13,177.27	11,654.04	38,344.52	35,320.71	47,207.18
5	Profit before exceptional items and tax	963.10	1,001.19	452.06	2,560.30	1,589.00	3,501.42
6	Exceptional items	-	-	-	-	11.38	10.99
7	Profit before Tax	963.10	1,001.19	452.06	2,560.30	1,577.61	3,490.43
8	Tax Expense						
	Current Tax	333.72	448.17	74.75	1,041.03	326.83	656.31
	Deferred Tax	137.93	(81.56)	47.75	27.82	221.33	206.49
	Total Tax Expense	471.65	366.61	122.50	1,068.85	548.16	862.80
9	Profit for the period	491.45	634.58	329.56	1,491.45	1,029.45	2,627.63
10	Other comprehensive income						
I	Items that will not be reclassified to profit or loss						
a	gains / (losses) on defined benefit plans	(2.66)	(0.94)	(4.17)	(7.99)	(12.51)	(17.56)
b	Deferred tax adjustment on revaluation	6.78	6.77	-	20.33	-	14.30
c	Income tax relating to items that will not be reclassified to profit & loss	0.93	0.33	1.46	2.79	4.37	6.14
II	Net other comprehensive income not to be reclassified to profit or loss in subsequent periods:	5.05	6.16	(2.71)	15.13	(8.14)	2.88
	Other comprehensive income/(loss) for the period, net of income tax	5.05	6.16	(2.71)	15.13	(8.14)	2.88
11	Total comprehensive income/(loss) ('OCI')	496.50	640.74	326.85	1,506.58	1,021.31	2,630.50
12	Paid up equity share capital (Face value Rs. 10/- each)	1,323.77	1,323.77	1,323.77	1,323.77	1,323.77	1,323.77
13	Other equity excluding revaluation reserves (as per balance sheet of previous accounting year)	**	**	**	**	**	19,442.49
14	Earning per share (Face value Rs. 10/- each)						
	Basic (Rs.)	0.74*	0.96*	0.5*	2.25*	1.56*	3.97
	Diluted (Rs.)	0.74*	0.96*	0.5*	2.25*	1.56*	3.97

* Not annualised

** Not required to be shown



Chc

Corporate Off : SF 202, Peach Tree, C-Block, Sushant Lok-1, Gurgaon-122002

Website : www.aglsl.in • E-mail : investor@aglsl.in • Tel. 0124 - 4262305/07 • Fax : 0124 - 4262306

Notes:-

1. The above results for the quarter & nine months ended December 31, 2018 were reviewed by the Audit Committee & approved by the Board of Directors at its meeting held on February 4th, 2019. The statutory auditors have expressed unmodified opinion on the aforesaid results.

2. With effect from April 01, 2018, the Company has adopted IND AS-115 ('Revenue from contracts with customers') using the cumulative effect method and accordingly these financial results are prepared in accordance with recognition and measurement principles laid down in IND AS- 115. There were no adjustments required to the retained earnings as at April 01, 2018. Also, the application of IND AS-115 did not have any significant impact on recognition and measurement of revenue and related items in the financial results of the Company.

3. Segment Reporting

Business segment

The company's operation predominantly comprise of only one business segment- Income from Healthcare services.

Geographical information

Geographical information analyses the company's revenue by the Company's country of domicile (i.e. India) and other countries. In presenting the geographical information, segment revenue has been based on the geographical location of the customers.

Region	Quarter ended			Nine Months ended		Year ended
	31-Dec-18	30-Sep-18	31-Dec-17	31-Dec-18	31-Dec-17	31-Mar-18
India	8,413.96	8,255.33	7,891.97	24,430.08	23,590.04	32,366.33
Outside India	5,489.88	5,833.65	4,124.03	16,205.80	12,976.17	17,910.80
Total	13,903.84	14,088.98	12,016.00	40,635.89	36,566.21	50,277.13

Region	Carrying amount of Segment assets	
	31-Dec-18	31-Mar-18
India	39,307.03	36,275.14
Outside India	-	-
Total	39,307.03	36,275.14

4. The Company and its holding company i.e. Artemis Health Sciences Ltd, its ultimate holding company i.e. Artemis Global Life Sciences Ltd and its fellow subsidiary company i.e. Athena Eduspark Limited have decided to merge and the proposed Composite Scheme of Amalgamation between the aforesaid Companies and their respective shareholders and creditors under section 230 to 232 and other applicable provisions of Companies Act, 2013 have been approved in the meeting of the Board of Directors held on 09th May, 2018. Respective shareholders and Creditors have also approved proposed Composite Scheme of Amalgamation in their meetings held on 27th Jan 2019. Scheme of Amalgamation is subject to clearance by National Company Law Tribunal & other regulatory approvals.

5. The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS), as prescribed under section 133 of the Companies Act 2013, and the other recognised accounting practices and policies to the extent applicable.

6. Results for the quarter & nine months ended 31st December 2018 have been subjected to limited review by the auditors. The Ind AS compliant corresponding figures and nine months ended 31st December 2017 were not subject to limited review.

7..EPS is not annualised for the quarter/ Nine months ended December 31,2018 & December 31, 2017 and quarter ended September 30, 2018 .

8. Previous period figures have been regrouped / reclassified wherever necessary to correspond with the current period classification / disclosures.



PLACE: GURUGRAM
DATE: FEBRUARY 4, 2018

For and on behalf of the Board of Directors of
ARTEMIS GLOBAL LIFE SCIENCES LIMITED


ONKAR S. KANWAR
CHAIRMAN